Mass. Movers

Celldex Therapeutics rebounds on rating


Needham biotech Celldex Therapeutics Inc. rebounded a day after it reported a loss for 2012 and for the fourth quarter. Celldex reported a net loss of $16.8 million, or 27 cents per share, for the quarter, compared to loss of $12.7 million, or 29 cents, in 2011. For the twelve months, Celldex reported a net loss of $59.1 million, or $1.02 per share, compared to a loss of $44.8 million, or $1.13, last year. Friday’s jump came after analysts at Leerink Swann initiated coverage for Celldex with a rating of outperform, setting a price of $18.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of